^
Association details:
| Biomarker: | Immune response prediction signature |
|---|---|
| Cancer: | Clear Cell Renal Cell Carcinoma |
| Drug Class: | PD-L1 inhibitor |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Construction of a novel immune response prediction signature to predict the efficacy of immune checkpoint inhibitors in clear cell renal cell carcinoma patients
Published date:
05/25/2023
Excerpt:
...we intended to develop and characterize an immune response prediction signature (IRPS) to forecast the efficacy of immunotherapy….A ccRCC cohort with anti-PD-1 therapy was obtained as an external validation data set to verify the predictive value of IRPS....Patients in the IRPS low risk group had better PFS (HR:0.73; 95% CI: 0.54-1.0; P = 0.047).
DOI:
https://doi.org/10.1016/j.heliyon.2023.e15925